tiprankstipranks
Prelude Therapeutics reports Q3 EPS (43c), consensus (47c)
PremiumThe FlyPrelude Therapeutics reports Q3 EPS (43c), consensus (47c)
3M ago
Prelude Therapeutics price target lowered to $1 from $3 at Barclays
Premium
The Fly
Prelude Therapeutics price target lowered to $1 from $3 at Barclays
3M ago
Prelude Therapeutics presents new data from Phase 1 trial of PRT3789
Premium
The Fly
Prelude Therapeutics presents new data from Phase 1 trial of PRT3789
3M ago
Prelude Therapeutics reports results from Phase 1 trial of PRT3789
PremiumThe FlyPrelude Therapeutics reports results from Phase 1 trial of PRT3789
5M ago
Prelude Therapeutics Unveils Promising Cancer Treatment Data at ESMO
Premium
Company Announcements
Prelude Therapeutics Unveils Promising Cancer Treatment Data at ESMO
5M ago
Prelude Therapeutics announces publication of abstract on PRT3789
Premium
The Fly
Prelude Therapeutics announces publication of abstract on PRT3789
5M ago
Buy/Sell: Wall Street’s top 10 stock calls this week
PremiumThe FlyBuy/Sell: Wall Street’s top 10 stock calls this week
7M ago
Spirit Aero downgraded, Skyworks upgraded: Wall Street’s top analyst calls
Premium
The Fly
Spirit Aero downgraded, Skyworks upgraded: Wall Street’s top analyst calls
7M ago
Prelude Therapeutics downgraded to Underweight from Equal Weight at Barclays
Premium
The Fly
Prelude Therapeutics downgraded to Underweight from Equal Weight at Barclays
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100